These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 18616963)

  • 1. The hERG potassium channel and hERG screening for drug-induced torsades de pointes.
    Hancox JC; McPate MJ; El Harchi A; Zhang YH
    Pharmacol Ther; 2008 Aug; 119(2):118-32. PubMed ID: 18616963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety.
    Gintant GA; Su Z; Martin RL; Cox BF
    Toxicol Pathol; 2006; 34(1):81-90. PubMed ID: 16507548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The continuing evolution of torsades de pointes liability testing methods: is there an end in sight?
    Lee N; Authier S; Pugsley MK; Curtis MJ
    Toxicol Appl Pharmacol; 2010 Mar; 243(2):146-53. PubMed ID: 20005885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of HERG human K+ channel and IKr of guinea pig cardiomyocytes by prochlorperazine.
    Kim MD; Eun SY; Jo SH
    Eur J Pharmacol; 2006 Aug; 544(1-3):82-90. PubMed ID: 16860311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Torsades-de-Pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk.
    Gintant GA
    Pharmacol Ther; 2008 Aug; 119(2):199-209. PubMed ID: 18621077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
    Wang L; Wible BA; Wan X; Ficker E
    J Pharmacol Exp Ther; 2007 Feb; 320(2):525-34. PubMed ID: 17095614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies.
    Shah RR
    Novartis Found Symp; 2005; 266():251-80; discussion 280-5. PubMed ID: 16050273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
    Guo L; Guthrie H
    J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.
    Recanatini M; Poluzzi E; Masetti M; Cavalli A; De Ponti F
    Med Res Rev; 2005 Mar; 25(2):133-66. PubMed ID: 15389727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of methadone and heroin on human ether-à-go-go-related gene channels.
    Zünkler BJ; Wos-Maganga M
    Cardiovasc Toxicol; 2010 Sep; 10(3):161-5. PubMed ID: 20467834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electrophysiologic, pharmacokinetic, and pharmacodynamic values indicating a higher risk of torsades de pointes.
    Lin YL; Hsiao CL; Wu YC; Kung MF
    J Clin Pharmacol; 2011 Jun; 51(6):819-29. PubMed ID: 20547773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the ion works HTTM system.
    Guthrie H; Livingston FS; Gubler U; Garippa R
    J Biomol Screen; 2005 Dec; 10(8):832-40. PubMed ID: 16234341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early clinical development: evaluation of drug-induced torsades de pointes risk.
    Vik T; Pollard C; Sager P
    Pharmacol Ther; 2008 Aug; 119(2):210-4. PubMed ID: 18601950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac safety assays.
    Heijman J; Voigt N; Carlsson LG; Dobrev D
    Curr Opin Pharmacol; 2014 Apr; 15():16-21. PubMed ID: 24721649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A history of the role of the hERG channel in cardiac risk assessment.
    Rampe D; Brown AM
    J Pharmacol Toxicol Methods; 2013; 68(1):13-22. PubMed ID: 23538024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
    Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
    Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels.
    Gordon E; Lozinskaya IM; Lin Z; Semus SF; Blaney FE; Willette RN; Xu X
    Mol Pharmacol; 2008 Mar; 73(3):639-51. PubMed ID: 18042732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early evaluation of compound QT prolongation effects: a predictive 384-well fluorescence polarization binding assay for measuring hERG blockade.
    Deacon M; Singleton D; Szalkai N; Pasieczny R; Peacock C; Price D; Boyd J; Boyd H; Steidl-Nichols JV; Williams C
    J Pharmacol Toxicol Methods; 2007; 55(3):238-47. PubMed ID: 17141530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-induced block of cardiac HERG potassium channels and development of torsade de pointes arrhythmias: the case of antipsychotics.
    Calderone V; Testai L; Martinotti E; Del Tacca M; Breschi MC
    J Pharm Pharmacol; 2005 Feb; 57(2):151-61. PubMed ID: 15720777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting drug-hERG channel interactions that cause acquired long QT syndrome.
    Sanguinetti MC; Mitcheson JS
    Trends Pharmacol Sci; 2005 Mar; 26(3):119-24. PubMed ID: 15749156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.